Tag: keytruda

Posted on: December 3, 2019 Posted by: earlenehands Comments: 0

Pharma Industry News @27 April 2019 | PharmaState

Pharma Industry News @27 April 2019 | PharmaState Watch for Latest Pharma News like -J&J baby shampoo issue -Torrent Pharma observations -Merck’s … source: https://medinaportal.net Xem thêm các bài viết về Sức Khỏe: https://medinaportal.net/category/suc-khoe/

Posted on: December 1, 2019 Posted by: earlenehands Comments: 0

Martin E. Gutierrez, MD, on 2nd line treatment options following 1st line PD-L1 targeting agents

Dr. Gutierrez, Director, Phase I Program, Co-Chair of Thoracic Oncology, John Theurer Cancer Center, Hackensack Meridian Health, shares how he would treat 2nd line patients who previously received Keytruda or other PD-L1 targeting agents as a part of 1st line therapy source: https://medinaportal.net Xem thêm các bài viết về Sức Khỏe: https://medinaportal.net/category/suc-khoe/

Posted on: November 28, 2019 Posted by: earlenehands Comments: 0

Dr. Malhotra on Pembrolizumab During Concurrent Chemoradiation in NSCLC

Jyoti Malhotra, MD, MPH, medical oncologist, Rutgers Cancer Institute of New Jersey, and assistant professor of medicine, Robert Wood Johnson Medical School, Rutgers University, discusses a phase I multicenter trial of PD-1 blockade with pembrolizumab (Keytruda) with concurrent chemoradiation in patients with locally advanced, unresectable non–small cell lung cancer (NSCLC). To learn more, visit our website or social media pages: Website: Twitter: Facebook: LinkedIn: source: https://medinaportal.net Xem thêm các bài…

Posted on: November 24, 2019 Posted by: earlenehands Comments: 0

Advanced renal cell carcinoma treatment

Dr. Scot Ebbinghaus from Merck Research Laboratories discusses the recent European Medicines Agency’s Committee for Medicinal Products for Human Use … source: https://medinaportal.net Xem thêm các bài viết về Sức Khỏe: https://medinaportal.net/category/suc-khoe/

Posted on: November 21, 2019 Posted by: earlenehands Comments: 0

Final KEYNOTE-048 Results With Frontline Pembrolizumab in Recurrent/Metastatic HNSCC

Danny Rischin, MD, director, Division of Cancer Medicine, head, Department of Medical Oncology, Peter MacCallum Cancer Centre, discusses results from the protocol-specified final analysis of the phase III KEYNOTE-048 trial of pembrolizumab (Keytruda) as frontline therapy for recurrent/metastatic head and neck squamous cell carcinoma. source: https://medinaportal.net Xem thêm các bài viết về Sức Khỏe: https://medinaportal.net/category/suc-khoe/

Posted on: November 19, 2019 Posted by: earlenehands Comments: 0

“እቲ ዓይንኹም ዝረኣዮ ነገር ከይትርስዑ ተጠንቀቑ” (10ይ ክፋል)ERITREAN ORTHODOX NEW FILM 2019

ብናይ ኤርትራ ኦርቶዶክስ ተዋህዶ ቤት ትምህርቲ ሰንበት ቅድስት ድንግል ማርያም ቤተ ክርስቲያን መድኃኔ ዓለም ኣብ ቅድስ… source: https://medinaportal.net Xem thêm các bài viết về Sức Khỏe: https://medinaportal.net/category/suc-khoe/

Posted on: November 16, 2019 Posted by: earlenehands Comments: 0

Dr. Geiger on Challenges of Patients With CSCC Enrolled in KEYNOTE-630 Trial

Jessica Geiger, MD, medical oncologist, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, discusses challenges with the patient population enrolled in the phase III KEYNOTE-630 trial exploring the use of adjuvant pembrolizumab (Keytruda) in cutaneous squamous cell carcinoma (CSCC). Website: Twitter: Facebook: LinkedIn: source: https://medinaportal.net Xem thêm các bài viết về Sức Khỏe: https://medinaportal.net/category/suc-khoe/

Posted on: November 14, 2019 Posted by: earlenehands Comments: 0

Pharma Industry News @04 April 2019 | PharmaState

Pharma Industry News @04 April 2019 | PharmaState Watch for Latest Pharma News like: -Natco CEO donates Rs 15 cr worth shares to children eye research. source: https://medinaportal.net Xem thêm các bài viết về Sức Khỏe: https://medinaportal.net/category/suc-khoe/

Posted on: November 12, 2019 Posted by: earlenehands Comments: 0

MRK Stock | Merck & Co. Q1 2019 Earnings Call

KEYTRUDA helps Merck to report Q1 earnings beat, raises 2019 outlook April 30, 2019 Shares of the pharma giant Merck (MRK) rose 2% before the market hours after the company surpassed estimates on the headline numbers. The company’s strong results were powered by its blockbuster drug KEYTRUDA which continued its momentum from the last quarter. Based on the strong Q1 results, Merck has raised its 2019 outlook for revenue and…